The controversy over prescription drug costs accelerated with some companies jacking up prices to previously unseen heights, and others slapping six-digit price tags on the latest medicines for cancer and other hard-to-treat diseases. Yet, despite the microscopic scrutiny now being applied to drug makers, efforts to clamp down on the entire pharmaceutical industry are unlikely to hamper the brazen upstarts generating headlines, according to Sector & Sovereign Research analyst Richard Evans, who once made pricing decisions for Roche. We spoke with him about the trends and implications. This is an edited version.
No Comment